Change of the pattern of management of the kidney transplant patients with terminal stage of chronic renal failure

The review presents results of clinical use of mTOR inhibitors, in particular, everolimus, in immunosuppressive therapy regimens. It has been established that immunosuppressive therapy regimens including mTOR inhibitors are preferred in patients with high and moderate risk of graft loss.The analysis of the clinical use of mTOR inhibitors has provided evidence of the comparative incidence rate of wound complications and terms of surgical wound healing in the treatment with everolimus and the routine therapy.Results of clinical trials have evidenced that minimization of therapy with calcineurin inhibitors and switching patients to everolimus allows for improvement of remote results of the kidney transplantation both due to reduced risk of nephrotoxic effect of calcineurin inhibitors, and due to anti-tumour and antiviral effects.

Download Full-text

Immunosuppressive Management of Pediatric Kidney Transplant Recipients

Current Pharmaceutical Design ◽

10.2174/1381612826666200708133429 ◽

2020 ◽

Vol 26 (28) ◽

pp. 3451-3459

Author(s):

Tomáš Seeman

Keyword(s):

Immunosuppressive Therapy ◽

Kidney Transplant ◽

Induction Therapy ◽

Graft Loss ◽

Calcineurin Inhibitors ◽

Mtor Inhibitors ◽

Therapeutic Drug ◽

High Dose ◽

Transplant Recipients ◽

Kidney Transplant Recipients

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.

Download Full-text